Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins... Show more
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on exaluren, a ribosome-modulating drug candidate designed to treat rare kidney diseases caused by nonsense mutations. Because the company is pre-revenue, its quarterly results are less about sales and more about two signals: how efficiently it is spending capital and whether its clinical programs are progressing on schedule. The third quarter was particularly notable because it marked a transition from preparation to execution, with the first patients dosed in the pivotal Phase 2b EXACT study. After a $66.0 million public offering and an uplisting to the Nasdaq Capital Market in June 2026, investors are watching closely to see whether the company can convert its strengthened balance sheet into meaningful clinical milestones.
For the third quarter ended September 30, 2026, Eloxx reported a net loss of $5.5 million, or $(0.49) per share, beating the consensus estimate of $(0.59) per share by $0.10. The company reported no revenue for the period, matching expectations of $0. This compares with a net loss of $0.4 million, or $(0.58) per share, in the same quarter of 2025.
R&D expenses rose to $4.0 million from a net credit of $0.3 million a year ago, primarily due to higher clinical trial costs tied to the EXACT study as well as increased personnel expenses. General and administrative (G&A) expenses increased to $1.9 million from $0.5 million, reflecting higher professional fees, personnel costs, and overhead. Other income, net, was $0.4 million, aided by higher interest income on larger cash balances following the June public offering.
For the nine months ended September 30, 2026, the net loss was $13.8 million, or $(1.83) per share, compared with $4.0 million, or $(9.12) per share, in the prior-year period. All per-share figures reflect the one-for-eleven reverse stock split completed in May 2026.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage biopharmaceutical names like Eloxx, it offers a streamlined way to monitor comparable opportunities across the sector.
The stock traded lower following the announcement, falling roughly 3.8% on November 16, 2026. For a pre-revenue biotech, the market's focus is less on the earnings per share (EPS) beat and more on the trajectory of the clinical pipeline and the rate of cash burn. The widening net loss relative to the prior-year quarter reflects increased investment in clinical development, which is a normal and expected step for a company advancing a lead program into mid-stage trials. Investors appear to be weighing the progress on the EXACT and EXPRESS studies against the absence of near-term revenue, with sentiment largely driven by upcoming clinical data readouts rather than quarterly financial figures.
The most important catalysts for Eloxx now lie in its clinical programs rather than its income statement. The company expects to report topline data from the 16-week placebo-controlled portion of the Phase 2b EXACT study in nonsense mutation Alport syndrome by mid-2027, with final 32-week data by the end of 2027. These readouts will be pivotal in validating exaluren's mechanism and shaping the path toward later-stage development.
In parallel, the company has finalized the design of its 52-week EXPRESS study in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD), a condition the company estimates affects 40,000 to 50,000 people in the United States. Following FDA clearance of the investigational new drug (IND) application in October 2026, Eloxx plans to dose the first patient in the third quarter of 2027 and report 52-week topline data in the first half of 2029.
On the financial side, investors should monitor the pace of cash burn, which is expected to increase as enrollment accelerates across both trials. Management indicated that its $56.3 million cash balance should fund operations into 2028, providing runway through the initial EXACT readouts. Cost trends, enrollment timelines, and any regulatory designations will be key factors to watch in the quarters ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of novel therapeutics and drugs
Industry Biotechnology